UNSPSC 51434911: Chlorothiazide/reserpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434911 Chlorothiazide/reserpine, a Commodity code, nominally addresses a specific antihypertensive combination medication, but recent state and local activity under this code spans the broader pharmacy and emergency medical supply category—state purchasing offices and municipal emergency services are soliciting sealed competitive bids, requests for proposals, and requests for information for generic pharmaceuticals, over-the-counter products, and advanced life support medications with specific unit counts, expiration and shelf-life requirements, and firm pricing inclusive of freight and applicable taxes. The issuing bodies include city procurement departments (City of Tampa's Purchasing Department), state health and human services agencies (Texas Health and Human Services Commission), and state-level cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration). Vendors must hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance; maintain direct relationships with authorized pharmaceutical wholesalers where chargebacks are in place; provide comprehensive insurance coverage including commercial general liability of at least $5,000,000 per occurrence and network security and privacy liability of at least $2,000,000; and furnish Safety Data Sheets compliant with OSHA Hazard Communication Standards and accessibility documentation meeting WCAG 2.2 Level AA standards and Section 508 requirements.

Geographic activity concentrates in Texas, Minnesota, and Florida, with the Minnesota Multistate Cooperative Purchasing Alliance extending reach to Oregon and other participating jurisdictions. Representative recent opportunities include the City of Tampa's sealed bid for Advanced Life Support Medications (Bid No. 26-P-00188, due April 8, 2026, estimated contract value $40,000.00) supplying 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials with a one-year term and two optional one-year renewals; the Texas Health and Human Services Commission's Request for Information (HHS0017013, response deadline April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program with direct contracting outside of pharmacy benefit manager, group purchasing organization, and wholesaler arrangements; and the Minnesota Department of Administration's MMCAP Request for Proposal (S1070000015802, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with contract terms of two years for new vendors and incumbent amendments extending through June 30, 2028, requiring vendors to work through three authorized wholesalers and maintain pricing flexibility across flat, net, and WAC-minus formats.